anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Our aim was to study the additive effect of surgeon-administered adductor canal infiltration (SACI) over routine periarticular infiltration (PAI) on pain control [morphine consumption and pain score by the visual analog scale (VAS)] and early function [flexion and Timed Up and Go (TUG) test] post-total knee arthroplasty (TKA).
METHODS: We prospectively randomized 60 patients into 2 groups. Group I patients received the standard PAI, whereas in Group II, the patients received a SACI in addition to the PAI. The total volume of the injected drug and the postoperative pain management protocol were the same for all. The number of doses of patient-controlled analgesia (PCA) used for breakthrough pain was recorded as PCA consumption. For early function, flexion and the TUG test were used. The VAS score and PCA consumption were compared between the 2 groups by using analyses of variance with post hoc tests as indicated. The TUG test and flexion were compared using Student t tests. The level of significance was set at 0.05.
RESULTS: The PCA consumption in the first 6 hours was significantly higher in Group I (P = .04). The VAS at 6 hours was significantly lower in Group II (P = .042). The TUG test was comparable between the 2 groups preoperatively (P = .72) at 24 hours (P = .60) and 48 hours (P = .60) post-TKA. The flexion was comparable between the 2 groups preoperatively (P = .85) at 24 hours (P = .48) and 48 hours (P = .79) post-TKA.
CONCLUSIONS: Adding a SACI to PAI provides improved pain relief and reduces opioid consumption without affecting early function post-TKA. A SACI avoids the need for an anesthesiologist or specialized equipment with no added operating time and minimal added cost. We recommend routine use of SACI for all patients undergoing TKA.
PURPOSE: Provided are novel type of anti-HIV agents particularly for inhibiting reproduction of HIV in an individual infected with the virus. The anti-HIV agents act by a mechanism of action different from those already being clinically used or under development. CONSTITUTION: The anti-HIV agent comprises as an active component a ligand molecule binding to CD87. An anti-HIV pharmaceutical composition comprises as an active component ATF, or a fragment thereof or an analogue thereto having a specific binding affinity to CD87. A method for screening for an anti-HIV agent comprises separately bringing compounds to be tested into contact with CD87 and selecting from the compounds a compound that specifically binds to CD87. A method for preparing an anti-HIV pharmaceutical preparation comprises the steps of: separately bringing compounds to be tested into contact with CD87 and selecting from the compounds a compound that specifically binds to CD87; confirming that the selected compound has an anti-HIV activity; and providing the compound confirmed to have an anti-HIV activity, as an anti-HIV agent, in the form of a pharmaceutical preparation to be administered to a human.
The invention provides a hybrid electro-anatomical map coloring tool with draggable geodesic overlays. A method includes receiving two or more surface representations of at least a portion of an organ of a patient. Two or more received surface representations are registered with each other. One of the surface representations is selected as a base map. A draggable geodesic region is generated for at least one of the two or more surface representations that is not selected as the base map, wherein the geodesic region is configured to follow changing anatomical structures as the region is dragged on the base map. The draggable geodesic region is superimposed on the base map to generate a hybrid multi-layer representation, and the hybrid multi-layer representation is presented to the user.
The objective of this observational study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score \>10. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event. This is a prospective, single arm, multi-center trial. Up to 200 patients at up to 30 centers will be enrolled in the study. It is anticipated that up to 150 evaluable patients will be needed for analysis. The sample size estimate is based on the primary study functional outcome at 90 days as defined by a mRS of 0-2. Assuming that this observational study will have as outcome of 25% (37/150) mRS 0-2 at day 90, the expected two-sided exact binomial confidence interval is (18%, 32%). This sample size is adequate to estimate the mRS outcome of 0-2 at day 90 for the natural history of acute ischemic stroke.
PROBLEM TO BE SOLVED: To obtain a W/O-type anti-suntan cosmetic free from ultraviolet absorber, having excellent ultraviolet protecting effect and high safety to the skin, giving excellent feeling to the skin and effective for preventing the secondary sticking of the powder contained in the base material. SOLUTION: This anti-suntan cosmetic contains 20-60wt.% of a volatile component (e.g. light liquid paraffin), 0.1-1.5wt.% of an organic-modified clay mineral (e.g. dodecyltrimethylammonium chloride), 0.5-20wt.% of spherical resin powder (e.g. nylon powder) and 0.1-30wt.% of a film-forming agent (e.g. polyvinyl pyrrolidone). The cosmetic is preferably further incorporated with 1-20wt.% of an ultraviolet scattering agent (e.g. titanium oxide). It may further be compounded with various components ordinarily used in cosmetics, pharmaceuticals, etc. The cosmetic exhibits excellent ultraviolet protecting effect without using an ultraviolet absorber and is smoothly spreadable on the skin.
The recommended dosage is one drop (1.5 µg) in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. 

The dosage of XALATAN Sterile Ophthalmic Solution should not exceed once daily; the combined use of two or more prostaglandins, or prostaglandin analogs including XALATAN Sterile Ophthalmic Solution is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the intraocular pressure lowering effect or cause paradoxical elevations in IOP.

Reduction of the intraocular pressure starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours.

XALATAN may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Vaccines or sera are produced from micro-organisms by irradiating the micro-organisms with high speed electrons having a velocity equivalent to more than one million volts during one or more very short time periods lasting less than say 10-4 second so as to destroy their faculty of propagation without destroying their antigenic properties.  The irradiation may be from several directions simultaneously.  The micro-organisms may be placed in an electron permeable sealed container or sealed in the final bottle or ampoule and may be cooled below 0 DEG C before irradiation.  The sealed container may be avacuated or may contain an inert gas and may be rotated during irradiation to facilitate uniform treatment.  Examples are irradiated with 4 million volt electrons for 2 periods 10-6 second.  The source of radiation and the sealed container should be of the type described in Specification 673,924, [Group XL(a)]. Micro-organisms specified are bacteria such as Strep. hemolyticus, prodigiosus, sporogens, Staph. aureus, coli, tetani, subtilis, pneumoniae, proteus, pyoceaneus, dysenteriae, diphtheriae, tuberculosis, pertussis, anthacis, botulinus, and viruses such as rolled leaf, rabies, vaccinia, hog cholera, influenza, poliomyelitis, chicken leukemia, equine encephalitis, mumps, newcastle of fowl.  The Specification as open to inspection under Sect. 91 comprises also irradiation under pressure of 2,000 lbs./square inch at -20 DEG  to -100 DEG C.  This subject-matter does not appear in the Specification as accepted.
ETHNOPHARMACOLOGICAL RELEVANCE: Obesity has become a public burden worldwide due to its booming incidence and various complications, and browning of white adipose tissue (WAT) is recognized as a hopeful strategy to combat it. Blossom of Citrus aurantium L. var. amara Engl. (CAVA) is a popular folk medicine and dietary supplement used for relieving dyspepsia, which is recorded in the Chinese Materia Medica. Our previous study showed that blossom of CAVA had anti-obesity potential, while its role in browning of WAT was still unclear.
AIM OF THE STUDY: This study aimed to characterize the constituents in flavonoids from blossom of CAVA (CAVAF) and to clarify the anti-obesity capacities especially the effects on browning of WAT.
MATERIALS AND METHODS: Gradient ethanol eluents from blossom of CAVA were obtained by AB-8 macroporous resin. 3T3-L1 cells and pancreatic lipase inhibition assay were employed to investigate the potential anti-obesity effects in vitro. HPLC and UPLC/MS assays were performed to characterize the chemical profiles of different eluents. Network pharmacology and molecular docking assays were used to reveal potential anti-obesity targets. Furthermore, high-fat diet (HFD)-induced mice were constructed to explore the anti-obesity actions and mechanisms in vivo.
RESULTS: 30% ethanol eluents with high flavonoid content and great inhibition on proliferation of 3T3-L1 preadipocytes and pancreatic lipase activity were regarded as CAVAF. 19 compounds were identified in CAVAF. Network pharmacology analysis demonstrated that AMPK and PPARα were potential targets for CAVAF in alleviating obesity. Animal studies demonstrated that CAVAF intervention significantly decreased the body weight, WAT weight, serum TG, TC and LDL-C levels in HFD-fed obese mice. HFD-induced insulin resistance and morphological changes in WAT and brown adipose tissue were also markedly attenuated by CAVAF treatment. CAVAF supplementation potently inhibited iWAT inflammation by regulating IL-6, IL-1β, TNF-α and IL-10 mRNA expression in iWAT of mice. Furthermore, the gene expression levels of thermogenic markers including Cyto C, ATP synthesis, Cidea, Cox8b and especially UCP1 in iWAT of mice were significantly up-regulated by CAVAF administration. CAVAF intervention also markedly increased the expression levels of PRDM16, PGC-1α, SIRT1, AMPK-α1, PPARα and PPARγ mRNA in iWAT of mice.
CONCLUSION: CAVAF treatment significantly promoted browning of WAT in HFD-fed mice. These results suggested that flavonoid extracts from blossom of CAVA were probably promising candidates for the treatment of obesity.
PURPOSE: To prepare a granulate of good quality, comprising a therapeutically effective substance having a water solubility within a specific range and a microcrystalline cellulose, etc., containing a relatively large amount of an active substance and capable of forming a solid tablet having a satisfactory disintegration behavior. CONSTITUTION: This pharmaceutical granulate comprises a therapeutically effective substance, having <10wt.%, preferably <5wt.% water solubility (e.g. an amphoteric β-lactam antibiotic substance or a tetracycline antibiotic substance) and a cellulosic product which is a microcrystalline cellulose or a microfine cellulose or a mixture of both. The content of a wet binder substance is 0-0.5wt.%, preferably <0.1wt.% based on the therapeutically effective substance. The granulate is capable of uninterruptedly flowing through a flow cup orifice not wider than 12mm. The cellulosic product is used in an amount within the range of 20-100wt.%, preferably 35-45wt.% based on the therapeutically effective substance.
PURPOSE: The purpose of this study was to compare the rates of wound complications and heterotopic ossification (HO) between patients who underwent acute total elbow arthroplasty (TEA) and those who underwent delayed TEA performed for the treatment of distal humerus fractures. Our hypothesis was that delayed surgery will have fewer wound complications but a higher rate of HO.
METHODS: We retrospectively reviewed 104 patients who had undergone TEA performed at 1 of 3 institutions following a distal humerus fracture. The acute cohort, comprising 69 patients, underwent TEA within 2 weeks; the delayed cohort, comprising 35 patients, received treatment between 2 weeks and 6 months. The rates of wound complications, HO, clinically relevant HO (requiring excision or resulting in loss of functional range of motion), and reoperation were recorded. These patients were followed up for an average of 52 (interquartile range, 18.5-117) weeks.
RESULTS: Wound complications occurred in 10 patients (14.5%) in the early group and 7 (20.0%) in the delayed group. The overall rate of HO was 56.7% (59 patients). The rate of clinically relevant HO was 26.0% (27 patients), which was similar between the groups. Reoperation occurred in 20 patients (19.2%), which was similar between the groups. In the early group, 3 reoperations were performed for wound complications and 4 for HO. No patients required reoperation for these indications in the delayed group. The mean flexion-extension and supination-pronation arcs were 20°-130° and 80°-80°, respectively, which were similar between the groups. Rheumatoid arthritis and younger age were associated with increased odds of wound complications and reoperation.
CONCLUSIONS: The rates of reoperation, wound complications, and HO were overall higher than those previously reported; however, the study was underpowered to determine a difference between early and delayed treatment.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.
FIELD: medicine, therapy. SUBSTANCE: invention relates to macroincapsulation of secretory cells in hydrophilic gel, the use of macroincapsulating secretory cells and retention of secretory cells by macroincapsulation method. Macrogranule with secretory cells, in part, pancreatic islands, is formed from collagen or agarose. After polymerization of collagen the hardened macrogranule is covered with agarose solution and immersed in mineral oil. For treatment of patients with insulin-dependent diabetes mellitus, for example, the prepared macrogranules containing effective amount of secretory cells are implanted to patient. Macroincapsulation of secretory cells in hydrophilic gel provides the functionality and nonimmunogenicity of macrogranule which after transplantation is retained for the more time. EFFECT: improved method of preparing and treatment, valuable medicinal properties. 20 cl, 8 dwg
INTRODUCTION: Sickle cell disease (SCD) is an inherited disorder characterised by polymerisation of deoxygenated haemoglobin S and microvascular obstruction. The cardinal feature is generalised pain referred to as vaso-occlusive crises (VOC), multi-organ damage and premature death. SCD is the most prevalent inherited life-threatening disorders in the world and over 85% of world's 400,000 annual births occur low-and-middle-income countries. Hydroxyurea remained the only approved disease modifying therapy (1998) until the FDA approved L-glutamine (2017), Crizanlizumab and Voxelotor (2019) and gene therapies (Exa-cel and Lovo-cel, 2023).
AREAS COVERED: Clinical trials performed in the last 10 years (November 2013 - November 2023) were selected for the review. They were divided according to the mechanisms of drug action. The following pubmed central search terms [sickle cell disease] or [sickle cell anaemia] Hydroxycarbamide/ Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab, Mitapivat, Etavopivat, gene therapy, haematopoietic stem cell transplantation, and combination therapy.
EXPERT OPINION: We recommend future trials of combination therapies for specific complications such as VOCs, chronic pain and renal impairment as well as personalised medicine approach based on phenotype and patient characteristics. Following recent approval of gene therapy for SCD, the challenge is addressing the role of shared decision-making with families, global access and affordability.
The present invention provides a method and apparatus for implementing a training regimen which alleviates exaggerated sensory, perceptual, cognitive and/or emotional response problems. For example, in the aural domain, some autistic individuals are hypersensitive to one of the senses, e.g., sound. As discussed above, sounds at the specific frequency can cause discomfort to these autistic individuals even when presented at an intensity level which normally is not perceived as being too loud by most individuals. Similarly, tinnitus afflicted individuals also suffer from disconcerting perceived ringing sensations in their ears. The present invention hypothesizes that a catastrophic cascade of responses within a 'supergroup' of auditory neurons is triggered by a hypersensitive response to a particular frequency or range of frequencies. The self sustaining cascade is very much like an epileptic seizure in which the sudden involontary response of a relatively small group of neurons trigger responses in a supergroup of neurons located in the motor control region of the brain. In accordance with the present invention, the abnormally sensitive response problem associated with supergroups can be substantially alleviated via a remedial training regimen which emphasizes the redevelopment of the afflicted individual's ability to make fine sensory distinctions and/or the improvement of the individual's differential sensory acuteness. Providing the regimen to the individual consistently over a period of time increases the likelihood of normal or near normal sensory ability returning.
OBJECTIVE: A supportive environment for women with Hyperemesis Gravidarum is crucial but not always provided. There is a lack of research regarding Hyperemesis Gravidarum, its impact on the family, and the partner's perception of supporting their spouse. Thus, this study aims to explore partners' experiences of Hyperemesis Gravidarum during their spousés pregnancy.
METHODS: Data were gathered through 13 individual, semi-structured, in-depth, digital interviews with partners of women who had experienced Hyperemesis Gravidarum and analysed with Qualitative Content Analysis. The partners were recruited through advertisement on a social media platform and were exclusively males, representing 8 of 21 Swedish regions. The mean age was 34, and they had, on average, 1 previous child. The mean time from the experience to the interview was 12 months.
FINDINGS: The main theme, "Navigating in a maze without a map", explains partners' situation as stressful and demanding when their spouse suffers from Hyperemesis Gravidarum, with insufficient support and guidance from healthcare providers. The analysis resulted in three themes: "Standing alone with a demanding responsibility", "Being in a lottery when facing healthcare", and "Climbing the mountain together." The themes display challenges within everyday life and healthcare, as well as strained relations within the family.
CONCLUSION: Partners experience a need to support their spouse in every aspect of daily life and advocate for adequate healthcare. Healthcare professionals must support and acknowledge the partners' struggles during the demanding situation with Hyperemesis Gravidarum.
The management of Central Centrifugal Cicatricial Alopecia (CCCA) is challenging due to limited current treatments and a lack of randomized controlled trials. Management focuses on behavioral and styling modifications, in addition to symptomatic relief. Any potentially damaging hair care practices such as chemical relaxers, heat application to the scalp, and the use of hardening gels and sprays are discouraged. Many commonly used therapies are anti-inflammatory in nature, including intralesional steroids, topical steroids, oral antibiotics and increased frequency of hair washing with antidandruff shampoos. These treatments not only lead to improvement in pruritus and tenderness, but in some cases result in increased hair density. Currently, comparison studies of different treatments for CCCA subjects is limited. The aim is to determine if there is an advantage in using one particular anti-inflammatory therapy over another for relieving symptoms and promoting hair follicle regrowth.
The present invention provides a medical care platform and a cross-departmental information system. The medical care platform includes a hospital information system, a medical care information system, a plurality of hospital terminal devices, and a cross-departmental information system. Therein, the hospital information system stores medical records of patients. The medical care information system records the treatment information of patients. The cross-departmental information system is remotely connected to the hospital information system, the medical care information system, and the hospital terminal devices. Staffs of different departments are allowed to log in the cross-departmental information system through a hospital terminal device, so as to inquire medical records and treatment information of patients, and also to input or retrieve related information of different departments, thereby understanding the latest medical care status of patients.
Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.